Streetbeat News

Products Services

AZN

FLUMIST, a product associated with AstraZeneca, has received approval for self-administration in the U.S., potentially impacting its market reach and sales.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 8:34 pm

AAPL

The Federal Reserve cut interest rates by 50 basis points, surprising economists and boosting stock and gold prices to record highs. The Fed's pro-growth stance is expected to benefit small-cap stocks, while mortgage demand rises due to lower rates. Apple faces weaker iPhone demand, and GM expands EV charging access.

Portfolio Pulse from Piero Cingari

September 20, 2024 | 8:03 pm

BTCUSD

DOGEUSD

ETHUSD

SOLUSD

Cryptocurrency markets are trading sideways with Ethereum outperforming Bitcoin. Bitcoin's price is below $63,000, and traders are watching for potential test zones. Ethereum's performance is strong, with a 3% gain. Bitcoin's RSI has broken out of its downtrend, and its dominance is falling, aligning with historical trends.

Portfolio Pulse from Khyathi Dalal

September 20, 2024 | 7:38 pm

CVS

LLY

NVO

SNY

UNH

The FTC has filed a lawsuit against CVS Health, Cigna, and UnitedHealth's pharmacy benefit managers for allegedly inflating insulin prices through anti-competitive practices. The complaint highlights a rebate system that prioritizes higher-priced drugs, increasing costs for patients.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 7:26 pm

CVX

DRLL

WDS

XLE

Chevron Corporation has decided not to invest in Woodside Energy's Driftwood LNG project, opting instead to sell its U.S. gas directly. This aligns with Chevron's strategy to focus on upstream and downstream investments rather than midstream infrastructure. The company has long-term LNG agreements with Cheniere Energy and is converting engines on LNG carriers to reduce emissions. Chevron's shares are slightly up, and investors can gain exposure through ETFs like DRLL and XLE.

Portfolio Pulse from Lekha Gupta

September 20, 2024 | 7:18 pm

CRBP

NVO

SKYE

Novo Nordisk's phase 2a trial results for monlunabant, a CB1 inverse agonist, showed limited additional weight loss at higher doses, impacting stocks of Corbus Pharmaceuticals and Skye Bioscience. Both companies are developing similar weight loss drugs. Analysts have adjusted price targets for Corbus, and Skye's stock dropped significantly.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 7:18 pm

ICUI

ICU Medical's subsidiary, Smiths Medical, has recalled paraPAC Plus ventilators due to a loose outlet connector that can cause serious health risks, including death. The recall follows reports of one injury and one death. ICU Medical's stock fell 1.56% following the news.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 7:18 pm

ABBV

BMY

Bristol-Myers Squibb's acquisition of Karuna Therapeutics positions it to potentially launch KarXT, the first new schizophrenia treatment in 70 years, pending FDA approval. This could significantly impact the treatment landscape, though high costs and systemic healthcare challenges may limit access.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 7:12 pm

Bloom Energy anticipates that its shipment volumes to Korea will remain consistent in 2024 and the following years, similar to recent years.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 7:07 pm

MSFT

Microsoft is ending its Xbox Ambassadors program after 13 years, with a complete shutdown by October 15, 2024. The program's closure is part of a shift in community engagement strategies, focusing on Xbox Rewards and Xbox Research. This comes amid a challenging year for Microsoft Gaming, marked by layoffs and studio closures.

Portfolio Pulse from Franca Quarneti

September 20, 2024 | 7:06 pm